v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (7,405,000) $ (3,803,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock option compensation expense 1,421,000 1,107,000
Common stock issued for services 323,000 333,000
Credit loss expense 13,000 37,000
Amortization of debt discount 132,000 67,000
Amortization of right-of-use operating lease assets 101,000 55,000
Amortization of right-of-use finance lease asset 56,000 33,000
Operating lease liabilities (98,000) (50,000)
Finance lease liability (49,000) (43,000)
Gain on investment in South Korean joint venture 0 (9,000)
Depreciation expense 67,000 78,000
Changes in assets and liabilities:    
Accounts receivable (122,000) (2,368,000)
Inventories 7,000 (114,000)
Prepaid expenses and other assets 17,000 33,000
Deposits (106,000) 68,000
Contract liabilities (234,000) 0
Net cash used in operating activities (5,973,000) (3,948,000)
Cash flows from investing activities    
Equipment purchases (192,000) 0
Proceeds from note receivable 0 192,000
Net cash (used in) provided by investing activities (192,000) 192,000
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 647,000 793,000
Proceeds from note payable 0 50,000
Common stock issued for financing fee 85,000 0
Repayment of debt obligations (16,000) (9,000)
Proceeds from Clyra Medical debt obligations 3,395,000 1,261,000
Repayment of Clyra Medical line of credit (134,000) 0
Proceeds from Clyra Medical stock option exercise 5,000 0
Proceeds from Clyra Medical unit warrant offering 0 1,309,000
Net cash provided by financing activities 4,469,000 3,699,000
Net effect of foreign currency translation 1,000 (20,000)
Net change in cash (1,695,000) (77,000)
Cash and cash equivalents at beginning of period 3,883,000 3,548,000
Cash and cash equivalents at end of period 2,188,000 3,471,000
Supplemental disclosures of cash flow information    
Interest 342,000 37,000
Income taxes 0 0
Short-term lease payments not included in lease liabilities 17,000 12,000
Non-cash investing and financing activities    
Conversion of accounts receivable to a note receivable 0 3,764,000
Allocation of noncontrolling interest (2,614,000) 504,000
Fair value of Clyra Medical warrants issued as debt discount 353,000 162,000
Clyra Medical dividend Series A Preferred stock 173,000 172,000
Clyra Medical Common Stock [Member]    
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 0 295,000
BioLargo Energy Technologies, Inc (BETI) [Member]    
Cash flows from financing activities    
Proceeds from BETI unit offering 487,000 0
Entities, Excluding Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses 39,000 484,000
Accounts payable and accrued expenses 39,000 484,000
Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses (135,000) 144,000
Accounts payable and accrued expenses $ (135,000) $ 144,000